237 related articles for article (PubMed ID: 9349239)
1. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma.
Bramhall SR; Neoptolemos JP; Stamp GW; Lemoine NR
J Pathol; 1997 Jul; 182(3):347-55. PubMed ID: 9349239
[TBL] [Abstract][Full Text] [Related]
2. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
3. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart.
Soini Y; Satta J; Määttä M; Autio-Harmainen H
J Pathol; 2001 Jun; 194(2):225-31. PubMed ID: 11400152
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
5. Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080.
Tanaka K; Iwamoto Y; Ito Y; Ishibashi T; Nakabeppu Y; Sekiguchi M; Sugioka Y
Cancer Res; 1995 Jul; 55(13):2927-35. PubMed ID: 7796421
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma.
Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H
Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
8. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
Jones JL; Glynn P; Walker RA
J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
10. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology.
Polette M; Clavel C; Cockett M; Girod de Bentzmann S; Murphy G; Birembaut P
Invasion Metastasis; 1993; 13(1):31-7. PubMed ID: 8407209
[TBL] [Abstract][Full Text] [Related]
11. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
12. The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.
Jeffery N; McLean MH; El-Omar EM; Murray GI
Histopathology; 2009 Jun; 54(7):820-8. PubMed ID: 19635101
[TBL] [Abstract][Full Text] [Related]
13. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover.
Phillips PA; McCarroll JA; Park S; Wu MJ; Pirola R; Korsten M; Wilson JS; Apte MV
Gut; 2003 Feb; 52(2):275-82. PubMed ID: 12524413
[TBL] [Abstract][Full Text] [Related]
14. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas.
Théret N; Musso O; Turlin B; Lotrian D; Bioulac-Sage P; Campion JP; Boudjéma K; Clément B
Hepatology; 2001 Jul; 34(1):82-8. PubMed ID: 11431737
[TBL] [Abstract][Full Text] [Related]
15. Dynamic expression of matrix metalloproteinases (MMP-2, -9 and -14) and the tissue inhibitors of MMPs (TIMP-1, -2 and -3) at the implantation site during tubal pregnancy.
Bai SX; Wang YL; Qin L; Xiao ZJ; Herva R; Piao YS
Reproduction; 2005 Jan; 129(1):103-13. PubMed ID: 15615902
[TBL] [Abstract][Full Text] [Related]
16. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas.
Lebeau A; Nerlich AG; Sauer U; Lichtinghagen R; Löhrs U
Anticancer Res; 1999; 19(5B):4257-64. PubMed ID: 10628384
[TBL] [Abstract][Full Text] [Related]
17. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.
Nakamura H; Ueno H; Yamashita K; Shimada T; Yamamoto E; Noguchi M; Fujimoto N; Sato H; Seiki M; Okada Y
Cancer Res; 1999 Jan; 59(2):467-73. PubMed ID: 9927064
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer.
Gong YL; Xu GM; Huang WD; Chen LB
J Surg Oncol; 2000 Feb; 73(2):95-9. PubMed ID: 10694645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
